Tempus AI, Inc. (NASDAQ: TEM) is a healthcare technology company specializing in artificial intelligence (AI) applications to advance precision medicine. Founded in 2015 and headquartered in Chicago, Illinois, Tempus offers AI-driven diagnostics and data analytics services across various medical fields, including oncology, cardiology, radiology, and depression.

As of February 8, 2025, TEM’s stock is trading at $68.96, reflecting a 6.19% increase from the previous close. The day’s trading range was between $65.13 and $69.87, with an opening price of $66.50 and a volume of 16,336,858 shares.

In 2023, Tempus reported revenues of $531.82 million, a 65.85% increase from the previous year. The company incurred a net loss of $265.96 million, which was a 20.35% improvement over 2022.

Analysts maintain a “Buy” consensus for TEM, with an average 12-month price target of $59.60, suggesting a potential downside of approximately 12.78% from the current price. Price targets range from a low of $44.00 to a high of $74.00.

A significant development for Tempus is the recent acquisition of Ambry Genetics, a California-based genetic testing company, for $600 million in a cash-and-stock deal. This strategic move is expected to enhance Tempus’s capabilities in genetic testing and precision medicine.

Despite the company’s growth and strategic initiatives, investors should be mindful of potential risks, including integration challenges from acquisitions and the need to achieve profitability. The stock has experienced significant volatility, with a 52-week range between $22.89 and $79.49.

In summary, Tempus AI is at the forefront of integrating AI into healthcare, demonstrating substantial revenue growth and strategic expansion. However, investors should carefully consider the associated risks and the current valuation when making investment decisions.